120 related articles for article (PubMed ID: 31453862)
21. Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck.
Trieu V; Pinto H; Riess JW; Lira R; Luciano R; Coty J; Boothroyd D; Colevas AD
Oncologist; 2018 Jul; 23(7):764-e86. PubMed ID: 29540603
[TBL] [Abstract][Full Text] [Related]
22. Induction chemotherapy in head and neck cancers: Results and controversies.
Gau M; Karabajakian A; Reverdy T; Neidhardt EM; Fayette J
Oral Oncol; 2019 Aug; 95():164-169. PubMed ID: 31345386
[TBL] [Abstract][Full Text] [Related]
23. Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients.
Graziano V; Grassadonia A; Iezzi L; Vici P; Pizzuti L; Barba M; Quinzii A; Camplese A; Di Marino P; Peri M; Veschi S; Alberti S; Gamucci T; Di Gioacchino M; De Tursi M; Natoli C; Tinari N
Breast; 2019 Apr; 44():33-38. PubMed ID: 30611095
[TBL] [Abstract][Full Text] [Related]
24. Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck.
Tishler RB; Posner MR; Norris CM; Mahadevan A; Sullivan C; Goguen L; Wirth LJ; Costello R; Case M; Stowell S; Sammartino D; Busse PM; Haddad RI
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1036-44. PubMed ID: 16682134
[TBL] [Abstract][Full Text] [Related]
25. Toxicity profile and clinical outcomes in locally advanced head and neck cancer patients treated with induction chemotherapy prior to concurrent chemoradiation.
Ko EC; Genden EM; Misiukiewicz K; Som PM; Kostakoglu L; Chen CT; Packer S; Kao J
Oncol Rep; 2012 Feb; 27(2):467-74. PubMed ID: 22020564
[TBL] [Abstract][Full Text] [Related]
26. Induction chemotherapy with docetaxel, cisplatin, fluorouracil and l-leucovorin for locally advanced head and neck cancers: a modified regimen for Japanese patients.
Watanabe A; Taniguchi M; Sasaki S
Anticancer Drugs; 2003 Nov; 14(10):801-7. PubMed ID: 14597874
[TBL] [Abstract][Full Text] [Related]
27. Predictive Factors for Completion of TPF Induction Chemotherapy in Patients With Locally Advanced Head and Neck Cancer.
Nakano K; Seto A; Sasaki T; Shimbashi W; Fukushima H; Yonekawa H; Mitani H; Takahashi S
Anticancer Res; 2019 Aug; 39(8):4337-4342. PubMed ID: 31366527
[TBL] [Abstract][Full Text] [Related]
28. Feasibility and safety of dose-dense modified docetaxel-cisplatin or carboplatin and 5-fluorouracil regimen (mTPF) in locally advanced or metastatic head and neck cancers: a retrospective monocentric study.
Yossi S; Linot B; Peyraga G; Breheret R; Laccourreye L; Capitain O
Int J Clin Oncol; 2015 Dec; 20(6):1086-92. PubMed ID: 25931315
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Kim MJ; Kim SM; Jung HA; Hong JY; Chang WJ; Choi MK; Kim HS; Sun JM; Park K; Ahn MJ
Korean J Intern Med; 2019 Sep; 34(5):1107-1115. PubMed ID: 29914230
[TBL] [Abstract][Full Text] [Related]
30. Induction chemotherapy with docetaxel, cisplatin and capecitabine, followed by combined cetuximab and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck: a phase I-II study.
Perri F; Muto P; Argenone A; Ionna F; Longo F; Fulciniti F; Sandomenico F; Daponte A; Caponigro F
Oncology; 2013; 84(4):251-4. PubMed ID: 23428719
[TBL] [Abstract][Full Text] [Related]
31. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.
Schöffski P; Catimel G; Planting AS; Droz JP; Verweij J; Schrijvers D; Gras L; Schrijvers A; Wanders J; Hanauske AR
Ann Oncol; 1999 Jan; 10(1):119-22. PubMed ID: 10076732
[TBL] [Abstract][Full Text] [Related]
32. Correlation of Ki-67 Proliferative Antigen Expression and Tumor Response to Induction Chemotherapy Containing Cell Cycle-Specific Agents in Head and Neck Squamous Cell Carcinoma.
Chatzkel J; Lewis JS; Ley JC; Wildes TM; Thorstad W; Gay H; Daly M; Jackson R; Rich J; Paniello R; Nussenbaum B; Liu J; Siegel BA; Dehdashti F; Adkins D
Head Neck Pathol; 2017 Sep; 11(3):338-345. PubMed ID: 28025779
[TBL] [Abstract][Full Text] [Related]
33. Possible surrogate marker for an effective dose-dense chemotherapy in treating ovarian cancer.
Huang CY; Yang YC; Wang KL; Chen TC; Chen JR; Weng CS; Chien HJ; Chang CL
Taiwan J Obstet Gynecol; 2016 Jun; 55(3):405-9. PubMed ID: 27343324
[TBL] [Abstract][Full Text] [Related]
34. A phase I study of cabazitaxel in combination with platinum and 5-fluorouracil (PF) in locally advanced squamous cell carcinoma of head and neck (LA-SCCHN).
Camille N; Rozehnal J; Roy E; Uczkowski D; Olson A; Genden E; Teng M; Bakst R; Gupta V; Posner M; Misiukiewicz K
Oral Oncol; 2017 Aug; 71():99-104. PubMed ID: 28688700
[TBL] [Abstract][Full Text] [Related]
35. Neutrophil-to-lymphocyte ratio is superior to platelet-to-lymphocyte ratio as a prognostic predictor in advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy.
Guo D; Li M; Chen D; Jing W; Zhu H; Fu L; Kong L; Yue J; Yu J
Future Oncol; 2019 Feb; 15(6):625-635. PubMed ID: 30430864
[TBL] [Abstract][Full Text] [Related]
36. Induction docetaxel and S-1 followed by concomitant radiotherapy with low-dose daily cisplatin in locally advanced head and neck carcinoma.
Kim HR; Lee CG; Choi EC; Kim JH; Koh YW; Cho BC
Head Neck; 2016 Apr; 38 Suppl 1():E1653-9. PubMed ID: 26890965
[TBL] [Abstract][Full Text] [Related]
37. Pretreatment lymphocyte-to-monocyte ratio as an independent prognostic factor for head and neck cancer.
Kano S; Homma A; Hatakeyama H; Mizumachi T; Sakashita T; Kakizaki T; Fukuda S
Head Neck; 2017 Feb; 39(2):247-253. PubMed ID: 27617428
[TBL] [Abstract][Full Text] [Related]
38. Neutrophil and Platelet to Lymphocyte Ratios in Associating with Blood Glucose Admission Predict the Functional Outcomes of Patients with Primary Brainstem Hemorrhage.
Fan Z; Hao L; Chuanyuan T; Jun Z; Xin H; Sen L; Juan Q; Cao Y; Mu Y
World Neurosurg; 2018 Aug; 116():e100-e107. PubMed ID: 29689388
[TBL] [Abstract][Full Text] [Related]
39. Promising long-term results with attenuated adverse effects by methotrexate-containing sequential chemoradiation therapy in locally advanced head and neck squamous cell carcinoma.
Tsai TL; Chu PY; Tai SK; Wang YF; Yang MH; Wang LW; Lirng JF; Chang SY
Jpn J Clin Oncol; 2011 Oct; 41(10):1182-93. PubMed ID: 21862506
[TBL] [Abstract][Full Text] [Related]
40. [Observance and results of concurrent chemoradiotherapy after induction chemotherapy by docetaxel, cisplatin and 5-fluoro-uracil for locally advanced head and neck cancers].
Calderon B; Guerder C; Resbeut M; Fakhry N; Dupuis C; Cowen D
Cancer Radiother; 2016 Apr; 20(2):83-90. PubMed ID: 26969244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
